These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 31005568)

  • 21. Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
    Haragan A; Field JK; Davies MPA; Escriu C; Gruver A; Gosney JR
    Lung Cancer; 2019 Aug; 134():79-84. PubMed ID: 31320000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice.
    Villaruz LC; Ancevski Hunter K; Kurland BF; Abberbock S; Herbst C; Dacic S
    Histopathology; 2019 Jan; 74(2):269-275. PubMed ID: 30105871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1
    Zhang L; Zhang X; Liu Y; Zhang T; Wang Z; Gu M; Li Y; Wang DD; Li W; Lin PP
    Cancer Lett; 2020 Jan; 469():355-366. PubMed ID: 31678168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating tumor cells counts are associated with CD8+ T cell levels in programmed death-ligand 1-negative non-small cell lung cancer patients after radiotherapy: A retrospective study.
    Liu Q; Zhao C; Jiang P; Liu D
    Medicine (Baltimore); 2021 Jul; 100(29):e26674. PubMed ID: 34398034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneity and prognosis of programmed cell death-ligand 1 expression in the circulating tumor cells of non-small cell lung cancer.
    Wang HL; Wu JQ; Wang Y; Yu J; Mao XN; Li ZR; Niu HR; Jin CL; Wang XJ; Yan ZH; Yi L; Yang B; Wei PJ; Zhang HT; Zhang SC
    Neoplasma; 2021 Jul; 68(4):823-831. PubMed ID: 34097427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
    Liu Y; Zugazagoitia J; Ahmed FS; Henick BS; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
    Clin Cancer Res; 2020 Feb; 26(4):970-977. PubMed ID: 31615933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients.
    Abdo M; Belloum Y; Heigener D; Welker L; von Weihe S; Schmidt M; Heuer-Olewinski N; Watermann I; Szewczyk M; Kropidlowski J; Pereira-Veiga T; Elmas H; Perner S; Steurer S; Wikman H; Pantel K; Reck M
    Mol Oncol; 2023 May; 17(5):737-746. PubMed ID: 36892210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
    Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
    Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy.
    Zhou Y; Zhou J; Hao X; Shi H; Li X; Wang A; Hu Z; Yang Y; Jiang Z; Wang T
    Breast Cancer Res Treat; 2023 Jul; 200(2):281-291. PubMed ID: 37227611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients.
    Kumar S; Pandey M; Mir IA; Mukhopadhyay A; Sharawat SK; Jain D; Saikia J; Malik PS; Kumar S; Mohan A
    Hum Cell; 2022 Jan; 35(1):286-298. PubMed ID: 34786661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer.
    Nakamura S; Hayashi K; Imaoka Y; Kitamura Y; Akazawa Y; Tabata K; Groen R; Tsuchiya T; Yamasaki N; Nagayasu T; Fukuoka J
    PLoS One; 2017; 12(10):e0186192. PubMed ID: 29049375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
    Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
    Shien K; Papadimitrakopoulou VA; Wistuba II
    Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
    Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
    Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor.
    Kennedy LC; Lu J; Kuehn S; Ramirez AB; Lo E; Sun Y; U'Ren L; Chow LQM; Chen Z; Grivas P; Kaldjian EP; Gadi VK
    Target Oncol; 2022 May; 17(3):329-341. PubMed ID: 35696014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
    Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
    Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
    Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
    Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.